Forster Eliot 4
4 · Protalix BioTherapeutics, Inc. · Filed Sep 4, 2025
Insider Transaction Report
Form 4
Forster Eliot
Director
Transactions
- Award
Common Stock
2025-09-03+7,500→ 7,500 total(indirect: By Trust) - Award
Stock Options (Right to Buy)
2025-09-03+15,000→ 15,000 totalExercise: $1.64Exp: 2035-09-03→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
- [F2]The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.
- [F3]Does not include options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033,